Walleye Capital LLC bought a new stake in shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 5,000,000 shares of the company's stock, valued at approximately $2,040,000. Walleye Capital LLC owned 5.30% of Unicycive Therapeutics as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Great Point Partners LLC acquired a new stake in Unicycive Therapeutics during the 3rd quarter valued at approximately $3,491,000. Acuta Capital Partners LLC bought a new stake in shares of Unicycive Therapeutics in the 3rd quarter valued at $807,000. Bleakley Financial Group LLC bought a new stake in shares of Unicycive Therapeutics in the 3rd quarter valued at $33,000. Finally, Virtu Financial LLC bought a new stake in shares of Unicycive Therapeutics in the 1st quarter valued at $36,000. Institutional investors and hedge funds own 40.42% of the company's stock.
Unicycive Therapeutics Stock Performance
UNCY traded down $0.00 during mid-day trading on Wednesday, reaching $0.71. 679,807 shares of the stock were exchanged, compared to its average volume of 1,242,413. The stock has a market capitalization of $73.70 million, a PE ratio of -0.73 and a beta of 2.36. The company has a 50 day moving average price of $0.48 and a two-hundred day moving average price of $0.50. Unicycive Therapeutics, Inc. has a 1 year low of $0.20 and a 1 year high of $1.82.
Wall Street Analysts Forecast Growth
UNCY has been the subject of several research analyst reports. Benchmark reiterated a "speculative buy" rating and issued a $3.00 price objective on shares of Unicycive Therapeutics in a research note on Friday, November 22nd. HC Wainwright reiterated a "buy" rating and issued a $2.50 price objective on shares of Unicycive Therapeutics in a research note on Tuesday, November 12th. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Unicycive Therapeutics has a consensus rating of "Buy" and a consensus price target of $5.13.
Check Out Our Latest Stock Analysis on Unicycive Therapeutics
About Unicycive Therapeutics
(
Free Report)
Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.
Read More
Before you consider Unicycive Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Unicycive Therapeutics wasn't on the list.
While Unicycive Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
